JP2018520685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520685A5 JP2018520685A5 JP2018502133A JP2018502133A JP2018520685A5 JP 2018520685 A5 JP2018520685 A5 JP 2018520685A5 JP 2018502133 A JP2018502133 A JP 2018502133A JP 2018502133 A JP2018502133 A JP 2018502133A JP 2018520685 A5 JP2018520685 A5 JP 2018520685A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- seq
- nos
- strand
- monomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 58
- 239000000178 monomer Substances 0.000 claims 23
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 3
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- IQFYYKKMVGJFEH-GJMOJQLCSA-N 1-[(2r,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-GJMOJQLCSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims 1
- 208000035657 Abasia Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960005311 telbivudine Drugs 0.000 claims 1
- XXYIANZGUOSQHY-XLPZGREQSA-N thymidine 3'-monophosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)C1 XXYIANZGUOSQHY-XLPZGREQSA-N 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193997P | 2015-07-17 | 2015-07-17 | |
| US62/193,997 | 2015-07-17 | ||
| PCT/US2016/042694 WO2017015175A1 (en) | 2015-07-17 | 2016-07-17 | Compositions and agents against hepatitis b virus and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520685A JP2018520685A (ja) | 2018-08-02 |
| JP2018520685A5 true JP2018520685A5 (enExample) | 2019-03-28 |
| JP6924744B2 JP6924744B2 (ja) | 2021-08-25 |
Family
ID=57775056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502133A Active JP6924744B2 (ja) | 2015-07-17 | 2016-07-17 | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170016000A1 (enExample) |
| EP (1) | EP3325097B1 (enExample) |
| JP (1) | JP6924744B2 (enExample) |
| CN (1) | CN108136206B (enExample) |
| AU (1) | AU2016296592B2 (enExample) |
| CA (1) | CA2996722A1 (enExample) |
| TW (1) | TWI761311B (enExample) |
| WO (1) | WO2017015175A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG194751A1 (en) | 2011-06-30 | 2013-12-30 | Arrowhead Res Corp | Compositions and methods for inhibiting gene expression of hepatitis b virus |
| WO2017027350A2 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
| EP3472346B1 (en) | 2016-06-17 | 2023-01-18 | F. Hoffmann-La Roche AG | Papd5 and papd7 inhibitors for treating a hepatitis b infection |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| TW202424191A (zh) | 2017-10-16 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子 |
| WO2019105418A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| KR20250107294A (ko) | 2017-12-01 | 2025-07-11 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도 |
| JP7273417B2 (ja) * | 2017-12-01 | 2023-05-15 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| WO2019105419A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| DK3732185T3 (da) | 2017-12-29 | 2025-03-31 | Suzhou Ribo Life Science Co Ltd | Konjugater og fremstilling og anvendelse heraf |
| SG11202009680XA (en) | 2018-04-05 | 2020-10-29 | Hoffmann La Roche | Use of fubp1 inhibitors for treating hepatitis b virus infection |
| US12247203B2 (en) | 2018-05-16 | 2025-03-11 | Alnylam Pharmaceuticals, Inc. | Modified RNA agents with reduced off-target effect |
| WO2019240504A1 (en) * | 2018-06-12 | 2019-12-19 | Am Sciences Co., Ltd. | Modified oligonucleotides for inhibition of target gene expression |
| KR102273071B1 (ko) * | 2018-06-12 | 2021-07-05 | 주식회사 에이엠사이언스 | B형 간염 예방 또는 치료용 조성물 |
| PE20220013A1 (es) | 2018-07-03 | 2022-01-11 | Hoffmann La Roche | Oligonucleotidos para modular la expresion de tau |
| BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
| EP3842534A4 (en) * | 2018-08-21 | 2022-07-06 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE |
| WO2020063198A1 (zh) | 2018-09-30 | 2020-04-02 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| EP3974530A4 (en) | 2019-05-22 | 2023-07-12 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHOD OF MANUFACTURE AND USE |
| CA3139195A1 (en) | 2019-05-22 | 2020-11-26 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| JP7610849B2 (ja) | 2019-05-24 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN110218728A (zh) * | 2019-06-28 | 2019-09-10 | 厦门甘宝利生物医药有限公司 | 一种新化合物及其应用 |
| WO2021107097A1 (ja) * | 2019-11-28 | 2021-06-03 | 株式会社ボナック | Ｂ型肝炎治療用核酸分子 |
| JP7653997B2 (ja) | 2019-12-19 | 2025-03-31 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用 |
| CN114867856A (zh) | 2019-12-19 | 2022-08-05 | 豪夫迈·罗氏有限公司 | Saraf抑制剂用于治疗乙型肝炎病毒感染的用途 |
| CN114829601A (zh) | 2019-12-19 | 2022-07-29 | 豪夫迈·罗氏有限公司 | Sbds抑制剂用于治疗乙型肝炎病毒感染的用途 |
| JP7634542B2 (ja) | 2019-12-19 | 2025-02-21 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用 |
| JP2023506540A (ja) | 2019-12-19 | 2023-02-16 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用 |
| US20220056451A1 (en) * | 2020-07-27 | 2022-02-24 | Aligos Therapeutics, Inc. | Hbv binding oligonucleotides and methods of use |
| JP2023538630A (ja) | 2020-08-21 | 2023-09-08 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用 |
| KR20230104652A (ko) * | 2020-11-06 | 2023-07-10 | 아뷰터스 바이오파마 코포레이션 | 변형된 siRNA를 포함하는 표적화된 접합체 |
| EP4265724A4 (en) * | 2020-12-18 | 2025-11-19 | Olix Pharmaceuticals Inc | ARNI AGENT TO INHIBIT THE EXPRESSION AND USE OF HBV |
| WO2022147304A1 (en) * | 2020-12-31 | 2022-07-07 | Arcturus Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| CN114767704B (zh) * | 2021-01-21 | 2024-06-14 | 圣诺制药公司 | 一种能够靶向乙型肝炎病毒的药物构造及药物组合物 |
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
| CN115267193B (zh) * | 2022-09-20 | 2022-12-27 | 北京大学 | 用于判断生物样本中HBsAg来源的方法及系统和用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CA2485256A1 (en) | 2002-05-10 | 2003-11-20 | Inex Pharmaceuticals Corporation | Pathogen vaccines and methods for using the same |
| US20070027099A1 (en) * | 2003-05-19 | 2007-02-01 | Lin Marie C | Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA) |
| US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| DK2270162T3 (en) | 2003-06-12 | 2019-01-21 | Alnylam Pharmaceuticals Inc | PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING |
| EP1765990A4 (en) | 2004-05-19 | 2008-07-09 | Melbourne Health | THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC AGENTS AGAINST HEPATITIS B |
| ES2441791T3 (es) | 2004-10-01 | 2014-02-06 | Novartis Vaccines And Diagnostics, Inc. | Moléculas de ARN de interferencia pequeñas modificadas y métodos de uso |
| US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
| US20080096839A1 (en) | 2005-03-09 | 2008-04-24 | Mogam Biotechnology Research Institute | Small Interfering Rna and Pharmaceutical Composition for Treatment of Hepatitis B Comprising the Same |
| CA2683063A1 (en) | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| US8314227B2 (en) | 2007-05-22 | 2012-11-20 | Marina Biotech, Inc. | Hydroxymethyl substituted RNA oligonucleotides and RNA complexes |
| KR20100069679A (ko) | 2007-09-17 | 2010-06-24 | 재단법인 목암생명공학연구소 | ＨＢＶ 또는 ＨＣＶ의 유전자 발현을 하향 조절하는 ｓｉＲＮＡ의 혈청 안정성 향상 및 면역 반응 저감 방법 |
| WO2009106999A2 (en) | 2008-02-28 | 2009-09-03 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Hollow nanoparticles and uses thereof |
| US20100015708A1 (en) | 2008-06-18 | 2010-01-21 | Mdrna, Inc. | Ribonucleic acids with non-standard bases and uses thereof |
| BRPI0922355A8 (pt) * | 2008-12-03 | 2017-12-12 | Marina Biotech Inc | Ácidos nucléicos, métodos para reduzir a expressão de um gene em uma célula in vitro, uso do ácido nucléico, complexo de rna e uso do complexo de rna |
| KR20120095397A (ko) | 2009-10-16 | 2012-08-28 | 글락소 그룹 리미티드 | Ｈｂｖ 안티센스 억제제 |
| JP2013537423A (ja) | 2010-08-17 | 2013-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| MX347253B (es) | 2011-04-21 | 2017-04-20 | Ionis Pharmaceuticals Inc | Modulación de la expresión del virus de hepatitis b (vhb). |
| SG194751A1 (en) * | 2011-06-30 | 2013-12-30 | Arrowhead Res Corp | Compositions and methods for inhibiting gene expression of hepatitis b virus |
| EP2771466A1 (en) | 2011-10-28 | 2014-09-03 | University Of The Witwatersrand, Johannesburg | Inhibition of viral gene expression |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| NZ705730A (en) | 2012-08-30 | 2016-06-24 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
| CN105103603A (zh) | 2012-12-05 | 2015-11-25 | 诺基亚通信公司 | 用于流量导向的方法和网络元件 |
| CN105792832B (zh) | 2013-10-04 | 2021-03-23 | 诺华股份有限公司 | 用于治疗乙肝病毒的有机化合物 |
| US9593077B2 (en) | 2013-11-18 | 2017-03-14 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| WO2015188194A1 (en) | 2014-06-06 | 2015-12-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| CR20170174A (es) | 2014-10-02 | 2017-11-07 | Protiva Biotherapeutics Inc | Composiciones y métodos para el silenciamiento de la expresión cénica del virus de la hepatitis b |
-
2016
- 2016-07-17 WO PCT/US2016/042694 patent/WO2017015175A1/en not_active Ceased
- 2016-07-17 CA CA2996722A patent/CA2996722A1/en active Pending
- 2016-07-17 AU AU2016296592A patent/AU2016296592B2/en not_active Ceased
- 2016-07-17 EP EP16828341.4A patent/EP3325097B1/en active Active
- 2016-07-17 JP JP2018502133A patent/JP6924744B2/ja active Active
- 2016-07-17 US US15/212,279 patent/US20170016000A1/en not_active Abandoned
- 2016-07-17 CN CN201680053632.1A patent/CN108136206B/zh active Active
- 2016-09-10 TW TW105129484A patent/TWI761311B/zh not_active IP Right Cessation
-
2018
- 2018-08-30 US US16/117,994 patent/US10961535B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520685A5 (enExample) | ||
| CN108136206B (zh) | 抗乙型肝炎病毒的组合物和药剂及其用途 | |
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| ES2988612T3 (es) | Agentes de ARNi para la infección por el virus de la hepatitis B | |
| AU2010248239B2 (en) | siRNA conjugate and preparation method thereof | |
| JP2018529732A5 (enExample) | ||
| US8936910B2 (en) | Method for selective oligonucleotide modification | |
| JP2016502858A5 (enExample) | ||
| US10538763B2 (en) | Compounds and methods for modulation of DUX4 | |
| CN115516092A (zh) | 血管生成素样3(ANGPTL3)的siRNA及其用途 | |
| JP2018530529A5 (enExample) | ||
| JP2019533472A5 (enExample) | ||
| JP2016520312A5 (enExample) | ||
| JP2015523854A5 (enExample) | ||
| TW201408309A (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| RU2020135289A (ru) | Применение ингибиторов fubp1 для лечения инфекции вирусом гепатита в | |
| RU2020115761A (ru) | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В | |
| KR20150006742A (ko) | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 | |
| JPWO2021041247A5 (enExample) | ||
| CN115702006A (zh) | 缀合基团及其缀合物 | |
| TW202237189A (zh) | 具有增強之肝靶向的ｓ抗原運輸抑制寡核苷酸聚合物之接合物 | |
| CN115768439A (zh) | 双链siRNA类似物的缀合物 | |
| KR101783444B1 (ko) | miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법 | |
| JP2018512140A5 (enExample) |